Literature DB >> 15718867

Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study.

Raj Vuppalanchi1, Smitha Marri, Dhanashri Kolwankar, Robert V Considine, Naga Chalasani.   

Abstract

BACKGROUND: Animal studies have suggested that adiponectin may play a role in the pathogenesis of alcoholic and nonalcoholic fatty liver disease. Studies are limited that evaluated the role of adiponectin in the pathogenesis of nonalcoholic steatohepatitis (NASH).
METHODS: To further our understanding of the role of adiponectin in the pathogenesis of NASH, the following studies were conducted. Serum adiponectin was measured and correlated with anthropometric and nutritional variables in 21 patients with biopsy-proven NASH and 19 age-, gender-, body mass index-, and body fat-matched controls. The effect of a mixed meal on serum adiponectin levels in a subgroup of patients (n = 24) with NASH and controls was assessed. In a separate cohort, liver samples belonging to healthy (n = 11), steatotic (n = 12), and NASH (n = 12) patients were used to further explore the role of adiponectin by measuring the expression of adiponectin and adiponectin receptor (AdipoR2) mRNA.
RESULTS: Patients with NASH had significantly lower levels of serum adiponectin than controls (4.9 +/- 2.7 vs. 7.3 +/- 3.5 microg/mL, P = 0.02). While no significant correlation existed between serum adiponectin and anthropometric or nutritional variables, it was independently associated with age, high density lipoprotein, and triglycerides. Mixed meal had no effect on serum adiponectin either in patients with NASH or in controls. There was no expression of adiponectin mRNA in any of liver samples studied. However, AdipoR2 mRNA expression was higher in NASH than in steatotic and normal liver tissue.
CONCLUSION: These data show that adiponectin may have a role in the pathogenesis of human NASH and should be investigated further.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15718867     DOI: 10.1097/01.mcg.0000152747.79773.2f

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  19 in total

1.  Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury.

Authors:  Mingyan Zhou; Aimin Xu; Paul K H Tam; Karen S L Lam; Lawrence Chan; Ruby L C Hoo; Jing Liu; Kim H M Chow; Yu Wang
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

Review 2.  What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

3.  Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease.

Authors:  Hongmei Zhang; Yixin Niu; Hongxia Gu; Shuai Lu; Weiwei Zhang; Xiaoyong Li; Zhen Yang; Li Qin; Qing Su
Journal:  J Clin Lab Anal       Date:  2018-11-02       Impact factor: 2.352

Review 4.  Adiponectin, a key adipokine in obesity related liver diseases.

Authors:  Christa Buechler; Josef Wanninger; Markus Neumeier
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

5.  Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice.

Authors:  Ke-Yong Wang; Akihide Tanimoto; Sohsuke Yamada; Xin Guo; Yan Ding; Teruo Watanabe; Takeshi Watanabe; Kimitoshi Kohno; Ken-Ichi Hirano; Hideo Tsukada; Yasuyuki Sasaguri
Journal:  Am J Pathol       Date:  2010-06-21       Impact factor: 4.307

Review 6.  Adiponectin action from head to toe.

Authors:  Karine Brochu-Gaudreau; Charlotte Rehfeldt; Richard Blouin; V Bordignon; Bruce D Murphy; Marie-France Palin
Journal:  Endocrine       Date:  2009-12-01       Impact factor: 3.633

Review 7.  Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance.

Authors:  Giovanni Tarantino; Silvia Savastano; Annamaria Colao
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

8.  Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis.

Authors:  M Nannipieri; F Cecchetti; M Anselmino; E Mancini; G Marchetti; A Bonotti; S Baldi; B Solito; M Giannetti; A Pinchera; F Santini; E Ferrannini
Journal:  Obes Surg       Date:  2008-10-16       Impact factor: 4.129

9.  Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients.

Authors:  Leyla Nazal; Arnoldo Riquelme; Nancy Solís; Margarita Pizarro; Alex Escalona; Mauricio Burotto; Juan Ignacio Méndez; Catalina Saint-Jean; María José Concha; Stefano Giovanni; Diego Awruch; Arturo Morales; Rene Baudrand; Gonzalo Carrasco; María Angélica Domínguez; Oslando Padilla; Manuel Espinoza; Juan Francisco Miquel; Flavio Nervi; Marco Arrese
Journal:  Obes Surg       Date:  2010-01-12       Impact factor: 4.129

10.  Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis.

Authors:  Shaikh Mizanoor Rahman; Ishtiaq Qadri; Rachel C Janssen; Jacob E Friedman
Journal:  J Lipid Res       Date:  2009-06-05       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.